BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21086687)

  • 21. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's: integrating the primary and secondary care guidelines.
    Macmahon D; Brooks D; Smith R
    Practitioner; 2000 Apr; 244(1609):370-8. PubMed ID: 10892059
    [No Abstract]   [Full Text] [Related]  

  • 23. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease: the case for novel treatment strategies.
    Stern MB; Freese A
    Exp Neurol; 1997 Mar; 144(1):2-3. PubMed ID: 9126142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R; Ling H
    J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guideline for the treatment of Parkinson's disease.
    Carr J; Kies B; Fine J;
    S Afr Med J; 2009 Oct; 99(10):755-6, 758. PubMed ID: 20128276
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical practice. Diagnosis and initial management of Parkinson's disease.
    Nutt JG; Wooten GF
    N Engl J Med; 2005 Sep; 353(10):1021-7. PubMed ID: 16148287
    [No Abstract]   [Full Text] [Related]  

  • 36. Drugs for Parkinson's disease.
    Cranwell-Bruce LA
    Medsurg Nurs; 2010; 19(6):347-9, 355; quiz 350. PubMed ID: 21337993
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of Parkinson's disease.
    Hely MA; Fung VS; Morris JG
    J Clin Neurosci; 2000 Nov; 7(6):484-94. PubMed ID: 11029227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical investigation of medicinal products in the treatment of Parkinson's disease (CPMP note for guidance). European Agency for Evaluation of Medicinal Products.
    Eur Neuropsychopharmacol; 1999 Sep; 9(5):443-9. PubMed ID: 10523052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newly-diagnosed Parkinson's disease: a therapeutic update.
    Pleet AB
    Geriatrics; 1992 Jan; 47(1):24-9. PubMed ID: 1729144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.